Protein clumps in the brain have long been associated with Alzheimer’s, but other potential causes of the condition are now ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

If you’re in your 30s, 40s or 50s, dementia might feel like a distant concern, something you associate with advanced age.

Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

To determine the underlying causes of neuronal vulnerability at the earliest stages of Alzheimer's Disease (AD), a research ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

For years, Alzheimer’s disease has been considered a brain disorder that leads to memory loss and cognitive decline. It’s a ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...